Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1095588


Republic of Korea In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015


Description: Republic of Korea In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015

Summary

This report is an essential source for in-depth information and data relating to Republic of Korea IIn vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Republic of Korea

Scope

- The report provides information on the Korean in vitro diagnostics market, broken down into detailed categories and segments such as In Vitro Diagnostics, Clinical Chemistry Test Reagents, Immunochemistry Test Reagents, Blood Test Reagents, Microbiology Test Reagents, Infectious Immunology, Test Reagents, Genetic Test Reagents, Self Testing, and Instruments.
- Total revenues, end users
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.

Reasons to buy

- Gain a strong understanding of the in vitro diagnostics devices market in Republic of Korea.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.


Contents: 1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of Markets Covered in This Report
3.1 In Vitro Diagnostics
3.2 Clinical Chemistry
3.2.1 Clinical Chemistry Rapid Tests & POC
3.2.2 Clinical Chemisty Analyzers
3.2.2.1 Automated Clinical Chemistry Analyzers
3.2.2.2 Semi-Automated Clinical Chemistry Analyzers
3.2.3 Electrolyte Chemistry Reagents
3.2.4 Enzyme Chemistry Reagents
3.2.5 Metabolite Chemistry Reagents
3.2.6 Urine Analysis
3.2.6.1 Urine Analyzer Reagents
3.2.6.2 Urine Analyzers
3.3 Genetic Testing
3.3.1 Acquired Gene or Chromosome Alterations
3.3.2 Inborn Gene or Chromosome Alterations
3.3.3 Other Genetic Tests
3.4 Haematology
3.4.1 Haematology Analyzers
3.4.2 Haematology Cell Counters
3.4.2.1 Differential Counters
3.4.2.2 Hemoglobinometers
3.4.3 Haematology Rapid Tests
3.4.3.1 Haemostasis Rapid Tests (Home Monitoring)
3.4.3.2 Rapid Haematology Tests (Point-Of-Care/Near Patient)
3.4.4 Haematology Reagents
3.4.4.1 Haematology Analyzer Reagents
3.4.4.2 Slide Stainers
3.4.5 Haemostasis
3.4.5.1 Coagulation Analyzers
3.4.5.2 Coagulation Factors
3.4.5.3 General Coagulation Tests
3.4.5.4 Platelet Factors
3.4.5.5 Special Coagulation Tests
3.4.6 Immunohaematology
3.4.6.1 ABO Typing
3.4.6.2 Antibody Detection
3.4.6.3 Rhesus Typing
3.5 Histology And Cytology
3.5.1 Cytology
3.5.1.1 Flow Cytometers
3.5.2 Histology
3.5.2.1 Monoclonal Antibodies
3.5.2.2 Tissue Typing Reagents
3.6 Immuno Chemistry
3.6.1 Disease Specific Immunochemistry
3.6.1.1 Auto-Immune Diseases
3.6.1.2 Cardiac Markers
3.6.1.3 Rheumatoid - Inflammatory Diseases Markers
3.6.1.4 Tumor markers
3.6.2 Drug Related Testing
3.6.2.1 Drugs of Abuse / Toxicology
3.6.2.2 Therapeutic Drug Monitoring
3.6.3 Endocrinology Tests
3.6.3.1 Fertility or Pregnancy Hormones
3.6.3.2 Individual and Specified Hormones
3.6.3.3 Thyroid Function Hormones
3.6.4 Immunochemistry Analyzers
3.6.4.1 Chemiluminescence Analyzers
3.6.4.2 ELISA Instruments
3.6.4.3 Immunofluorescence Analyzers
3.6.4.4 Radioimmunoassay Analyzers
3.6.5 Immunochemistry Rapid Tests
3.6.6 Organ Function Assays
3.6.7 Specific Proteins
3.7 Infectious Immunology
3.7.1 Bacteriology
3.7.2 Hepatitis Viruses
3.7.3 Other Virology
3.7.4 Retroviruses
3.8 Microbiology Culture
3.8.1 Bacterial Identification & Susceptibility Testing
3.8.2 Blood Culture
3.8.3 Immunological Culture Identification
3.8.4 Microbiology Analyzers
3.8.4.1 Automated Microbiology Analyzers
3.8.4.2 Semi-Automated Microbiology Analyzers
3.8.5 Mycobacteria Culture
3.8.6 Mycology Culture
3.8.7 Parasitology Culture
4 Healthcare Sector Review
4.1 Healthcare Expenditure
4.2 Healthcare Infrastructure
4.3 Healthcare Policy
5 Regulation System
5.1 Medical Equipment Approval Process
5.1.1 Classification
5.1.2 Premarket Notification for Class I Devices
5.1.3 Pre-market Approval for Class II, III and IV Devices
5.1.3.1 Technical Review:
5.1.3.2 Type Testing:
5.1.3.3 Applying for Product License:
5.1.3.4 KGMP Certification
5.1.4 License Fee
5.1.5 License Application Processing Duration
5.2 Post-market Surveillance
6 Pricing and Reimbursement
7 Distribution Structure
7.1 Distribution Structure
8 In Vitro Diagnostics In Republic of Korea
8.1 In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), 2000-2015
8.2 In Vitro Diagnostics, Republic of Korea, Company Share (2007-2008)
9 Clinical Chemistry In Republic of Korea
9.1 Clinical Chemistry Overall Revenue (2000-2015)
9.1.1 Clinical Chemistry Analyzers Revenue (2000-2015)
9.1.2 Urine Analysis Revenue (2000-2015)
9.2 Clinical Chemistry Distribution Share (2007-2008)
9.3 Clinical Chemistry, Republic of Korea, Company Share (2007-2008)
10 Genetic Testing In Republic of Korea
10.1 Genetic Testing Overall Revenue (2000-2015)
10.2 Genetic Testing Distribution Share (2007-2008)
10.3 Genetic Testing, Republic of Korea, Company Share (2007-2008)
11 Haematology In Republic of Korea
11.1 Haematology Overall Revenue (2000-2015)
11.1.1 Haematology Reagents Revenue (2000-2015)
11.1.2 Immunohaematology Revenue (2000-2015)
11.1.3 Haemostasis revenue (2000-2015)
11.1.4 Haematology Rapid Tests Revenue (2000-2015)
11.1.5 Haematology Cell Counters Revenue (2000-2015)
11.2 Haematology Distribution Share (2007-2008)
11.3 Haematology, Republic of Korea, Company Share (2007-2008)
12 Histology And Cytology In Republic of Korea
12.1 Histology And Cytology Overall Revenue (2000-2015)
12.1.1 Histology Revenue (2000-2015)
12.2 Histology And Cytology Distribution Share (2007-2008)
12.3 Histology And Cytology, Republic of Korea, Company Share (2007-2008)
13 Immuno Chemistry In Republic of Korea
13.1 Immuno Chemistry Overall Revenue (2000-2015)
13.1.1 Disease Specific Immunochemistry Revenue (2000-2015)
13.1.2 Drug Related Testing Revenue (2000-2015)
13.1.3 Endocrinology Tests Revenue (2000-2015)
13.1.4 Immunochemistry Analyzers Revenue (2000-2015)
13.2 Immuno Chemistry Distribution Share (2007-2008)
13.3 Immuno Chemistry, Republic of Korea, Company Share (2007-2008)
14 Infectious Immunology In Republic of Korea
14.1 Infectious Immunology Overall Revenue (2000-2015)
14.2 Infectious Immunology Distribution Share (2007-2008)
14.3 Infectious Immunology, Republic of Korea, Company Share (2007-2008)
15 Microbiology Culture In Republic of Korea
15.1 Microbiology Culture Overall Revenue (2000-2015)
15.1.1 Microbiology Analyzers Revenue (2000-2015)
15.2 Microbiology Culture Distribution Share (2007-2008)
15.3 Microbiology Culture, Republic of Korea, Company Share (2007-2008)
16 Overview of Key Companies in Republic of Korea In Vitro Diagnostics Market
16.1 F. Hoffmann-La Roche Ltd.
16.1.1 Company Overview
16.2 Siemens Healthcare
16.2.1 Company Overview
16.3 Sysmex Corporation
16.3.1 Company Overview
16.3.2 Sysmex Corporation Pipeline Products
16.3.2.1 Sysmex Corporation Pipeline Products By Equipment Type
16.3.2.2 Sysmex Corporation Pipeline Products By Development Stage
16.3.2.3 Sysmex Corporation Pipeline Products By Therapy Area
16.3.2.4 Sysmex Corporation Pipeline Products By News Summary
16.4 Abbott Laboratories
16.4.1 Company Overview
16.4.2 Abbott Laboratories Pipeline Products
16.4.2.1 Abbott Laboratories Pipeline Products By Equipment Type
16.4.2.2 Abbott Laboratories Pipeline Products By Development Stage
16.4.2.3 Abbott Laboratories Pipeline Products By Therapy Area
16.5 Beckman Coulter, Inc.
16.5.1 Company Overview
16.5.2 Beckman Coulter, Inc. Pipeline Products
16.5.2.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
16.5.2.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
16.5.2.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
16.5.2.4 Beckman Coulter, Inc. Pipeline Products By News Summary
16.6 Ortho-Clinical Diagnostics Inc.
16.6.1 Company Overview
16.6.2 Ortho-Clinical Diagnostics Inc. Pipeline Products
16.6.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type
16.6.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
16.6.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
16.7 OLYMPUS CORPORATION
16.7.1 Company Overview
16.8 Qiagen N.V.
16.8.1 Company Overview
16.9 bioMerieux S.A.
16.9.1 Company Overview
16.10 Bio-Rad Laboratories, Inc.
16.10.1 Company Overview
16.11 Phadia AB
16.11.1 Company Overview
16.11.2 Phadia AB Pipeline Products
16.11.2.1 Phadia AB Pipeline Products By Equipment Type
16.11.2.2 Phadia AB Pipeline Products By Development Stage
16.11.2.3 Phadia AB Pipeline Products By Therapy Area
16.11.2.4 Phadia AB Pipeline Products By News Summary
16.12 DiaSorin S.p.A
16.12.1 Company Overview
16.12.2 DiaSorin S.p.A Pipeline Products
16.12.2.1 DiaSorin S.p.A Pipeline Products By Equipment Type
16.12.2.2 DiaSorin S.p.A Pipeline Products By Development Stage
16.12.2.3 DiaSorin S.p.A Pipeline Products By Therapy Area
16.13 Becton, Dickinson and Company
16.13.1 Company Overview
16.14 Gen-Probe Incorporated
16.14.1 Company Overview
16.14.2 Gen-Probe Incorporated Pipeline Products
16.14.2.1 Gen-Probe Incorporated Pipeline Products By Equipment Type
16.14.2.2 Gen-Probe Incorporated Pipeline Products By Development Stage
16.14.2.3 Gen-Probe Incorporated Pipeline Products By Therapy Area
16.14.2.4 Gen-Probe Incorporated Pipeline Products By Clinical Trials
16.14.2.5 Gen-Probe Incorporated Pipeline Products By News Summary
16.15 Inverness Medical Innovations, Inc.
16.15.1 Company Overview
16.15.2 Inverness Medical Innovations, Inc. Pipeline Products
16.15.2.1 Inverness Medical Innovations, Inc. Pipeline Products By Equipment Type
16.15.2.2 Inverness Medical Innovations, Inc. Pipeline Products By Development Stage
16.15.2.3 Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area
16.15.2.4 Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials
16.15.2.5 Inverness Medical Innovations, Inc. Pipeline Products By News Summary
16.16 Mindray Medical International Limited
16.16.1 Company Overview
16.17 Boditech Med Inc.
16.17.1 Company Overview
16.18 Roche Diagnostics Korea Co., Ltd.
16.18.1 Company Overview
17 Financial Deals Landscape
17.1 Partnerships
17.1.1 DxS Signs Cross-Licensing Agreement with Epigenomics
17.1.2 Prodesse Enters Into A licensing Agreement With Abbott Laboratories
17.1.3 Seegene Enters Into An Agreement With Randox Laboratories
18 Recent Developments
18.1 Product News
18.1.1 Apr 29, 2009: Seegene Launches Seeplex Diarrhea ACE Detection Test
18.1.2 Mar 03, 2009: Seegene Announces The Launch Of Seeplex MTB ACE Detection Test
19 Appendix
19.1 Global Markets Direct Research Methodology
19.2 Secondary Research
19.3 Primary Research
19.4 Models
19.5 Forecasts
19.6 Expert Panel Validation
19.7 Currency Conversion
19.8 Contact Us
19.9 Disclaimer

Executive Summary

1.1 List of Tables
Table 1: Total Healthcare Expenditure, Republic of Korea, 2000 - 2007 25
Table 2: Hospital Wards by Specialty in Republic of Korea, 2003-2007 29
Table 3: Doctors by Specialty in Republic of Korea, 2003-2007 30
Table 4: Healthcare Institutions in Republic of Korea, 2001-2005 31
Table 5: Healthcare Personnel in Republic of Korea, 1975-2002 31
Table 6: Classification of Medical Equipment in Republic of Korea 33
Table 7: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), 2000-2015 41
Table 8: In Vitro Diagnostics, Republic of Korea, Cross-Category Analysis, 2000-2015 42
Table 9: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), Historic, 2000-2008 44
Table 10: In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), Forecast, 2008-2015 46
Table 11: In Vitro Diagnostics, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 47
Table 12: Clinical Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 49
Table 13: Clinical Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 51
Table 14: Clinical Chemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 52
Table 15: Clinical Chemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 53
Table 16: Urine Analysis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 54
Table 17: Urine Analysis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 55
Table 18: Clinical Chemistry, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 56
Table 19: Clinical Chemistry, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 57
Table 20: Genetic Testing, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 58
Table 21: Genetic Testing, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 59
Table 22: Genetic Testing, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 60
Table 23: Genetic Testing, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 61
Table 24: Haematology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 63
Table 25: Haematology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 65
Table 26: Haematology Reagents, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 66
Table 27: Haematology Reagents, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 67
Table 28: Immunohaematology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 68
Table 29: Immunohaematology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 69
Table 30: Haemostasis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 71
Table 31: Haemostasis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 73
Table 32: Haematology Rapid Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 74
Table 33: Haematology Rapid Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 75
Table 34: Haematology Cell Counters, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 76
Table 35: Haematology Cell Counters, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 77
Table 36: Haematology, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 78
Table 37: Haematology, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 79
Table 38: Histology And Cytology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 80
Table 39: Histology And Cytology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 81
Table 40: Histology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 82
Table 41: Histology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 83
Table 42: Histology And Cytology, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 84
Table 43: Histology And Cytology, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 85
Table 44: Immuno Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 87
Table 45: Immuno Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 89
Table 46: Disease Specific Immunochemistry, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 91
Table 47: Disease Specific Immunochemistry, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 93
Table 48: Drug Related Testing, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 94
Table 49: Drug Related Testing, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 95
Table 50: Endocrinology Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 96
Table 51: Endocrinology Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 97
Table 52: Immunochemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 98
Table 53: Immunochemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 99
Table 54: Immuno Chemistry, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 100
Table 55: Immuno Chemistry, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 102
Table 56: Infectious Immunology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 104
Table 57: Infectious Immunology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 106
Table 58: Infectious Immunology, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 107
Table 59: Infectious Immunology, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 109
Table 60: Microbiology Culture, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 111
Table 61: Microbiology Culture, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 113
Table 62: Microbiology Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 114
Table 63: Microbiology Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 115
Table 64: Microbiology Culture, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 116
Table 65: Microbiology Culture, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 117
Table 66: Sysmex Corporation Pipeline Products by Equipment Type 119
Table 67: Sysmex Corporation Pipeline Products By Development Stage 119
Table 68: Sysmex Corporation Pipeline Products By Therapy Area 119
Table 69: Sysmex Corporation Pipeline Products By News Summary 120
Table 70: Abbott Laboratories Pipeline Products by Equipment Type 121
Table 71: Abbott Laboratories Pipeline Products By Development Stage 121
Table 72: Abbott Laboratories Pipeline Products By Therapy Area 121
Table 73: Beckman Coulter, Inc. Pipeline Products by Equipment Type 123
Table 74: Beckman Coulter, Inc. Pipeline Products By Development Stage 124
Table 75: Beckman Coulter, Inc. Pipeline Products By Therapy Area 125
Table 76: Beckman Coulter, Inc. Pipeline Products By News Summary 125
Table 77: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type 126
Table 78: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage 127
Table 79: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area 127
Table 80: Phadia AB Pipeline Products by Equipment Type 130
Table 81: Phadia AB Pipeline Products By Development Stage 130
Table 82: Phadia AB Pipeline Products By Therapy Area 131
Table 83: Phadia AB Pipeline Products By News Summary 131
Table 84: DiaSorin S.p.A Pipeline Products by Equipment Type 132
Table 85: DiaSorin S.p.A Pipeline Products By Development Stage 132
Table 86: DiaSorin S.p.A Pipeline Products By Therapy Area 132
Table 87: Gen-Probe Incorporated Pipeline Products by Equipment Type 134
Table 88: Gen-Probe Incorporated Pipeline Products By Development Stage 135
Table 89: Gen-Probe Incorporated Pipeline Products By Therapy Area 135
Table 90: Gen-Probe Incorporated Pipeline Products By Clinical Trials 135
Table 91: Gen-Probe Incorporated Pipeline Products By News Summary 136
Table 92: Inverness Medical Innovations, Inc. Pipeline Products by Equipment Type 137
Table 93: Inverness Medical Innovations, Inc. Pipeline Products By Development Stage 138
Table 94: Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area 138
Table 95: Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials 138
Table 96: Inverness Medical Innovations, Inc. Pipeline Products By News Summary 139
Table 97: DxS Signs Cross-Licensing Agreement With Epigenomics 141
Table 98: Prodesse Enters Into A licensing Agreement With Abbott Laboratories 142
Table 99: Seegene Enters Into An Agreement With Randox Laboratories 143
Table 100: USD to Local Currency, Average Exchange Rate 2008 148


Companies Mentioned F. Hoffmann-La Roche Ltd. Siemens Healthcare Sysmex Corporation Abbott Laboratories Beckman Coulter, Inc. Ortho-Clinical Diagnostics Inc. OLYMPUS CORPORATION Qiagen N.V. bioMerieux S.A. Bio-Rad Laboratories, Inc. Phadia AB DiaSorin S.p.A Becton, Dickinson and Company Gen-Probe Incorporated Inverness Medical Innovations, Inc. Mindray Medical International Limited Boditech Med Inc. Roche Diagnostics Korea Co., Ltd.


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/1095588

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 16/02/2012 12:33:41
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Republic of Korea In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015
Web Address:
http://www.researchandmarkets.com/reports/1095588
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €1,886.00
Electronic (PDF) - Site License €3,772.00
Electronic (PDF) - Enterprisewide €5,659.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 16/02/2012 12:33:41

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)